XML 128 R112.htm IDEA: XBRL DOCUMENT v3.20.4
Stockholders' Equity - Summary of Restricted Stock Units (Details) - $ / shares
shares in Millions
12 Months Ended
Dec. 31, 2020
Dec. 31, 2019
Dec. 31, 2018
Service Based Restricted Stock      
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Number of Shares [Roll Forward]      
Restricted stock, outstanding, beginning balance (in shares) 0.3    
Restricted stock, exercised (in shares) (0.1)    
Restricted stock, outstanding, ending balance (in shares) 0.2 0.3  
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value [Abstract]      
Weighted average grant date fair value, beginning balance (in USD per share) $ 36.33    
Weighted average grant date fair value, exercised (in USD per share) 34.81    
Weighted average grant date fair value, granted (in USD per share)   $ 40.70 $ 29.74
Weighted average grant date fair value, ending balance (in USD per share) $ 39.90 $ 36.33  
Service Based Restricted Stock Units      
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Number of Shares [Roll Forward]      
Restricted stock, outstanding, beginning balance (in shares) 0.0    
Restricted stock, granted (in shares) 0.1    
Restricted stock, outstanding, ending balance (in shares) 0.1 0.0  
Restricted stock, expected to vest (in shares) 0.1    
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value [Abstract]      
Weighted average grant date fair value, beginning balance (in USD per share) $ 0    
Weighted average grant date fair value, granted (in USD per share) 46.00    
Weighted average grant date fair value, ending balance (in USD per share) 46.00 $ 0  
Weighted average grant date fair value, expected to vest (in USD per share) $ 46.00    
Performance Based Restricted Stock      
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Number of Shares [Roll Forward]      
Restricted stock, outstanding, beginning balance (in shares) 1.0    
Restricted stock, exercised (in shares) (0.4)    
Restricted stock, canceled (in shares) (0.1)    
Restricted stock, outstanding, ending balance (in shares) 0.5 1.0  
Restricted stock, expected to vest (in shares) 0.4    
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value [Abstract]      
Weighted average grant date fair value, beginning balance (in USD per share) $ 29.41    
Weighted average grant date fair value, exercised (in USD per share) 25.01    
Weighted average grant date fair value, granted (in USD per share)   $ 37.27 $ 26.36
Weighted average grant date fair value, canceled (in USD per share) 29.00    
Weighted average grant date fair value, ending balance (in USD per share) 36.59 $ 29.41  
Weighted average grant date fair value, expected to vest (in USD per share) $ 35.52    
Restricted stock and restricted stock units, performance based      
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Number of Shares [Roll Forward]      
Restricted stock, outstanding, beginning balance (in shares) 0.0    
Restricted stock, granted (in shares) 0.4    
Restricted stock, outstanding, ending balance (in shares) 0.4 0.0  
Restricted stock, expected to vest (in shares) 0.2    
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value [Abstract]      
Weighted average grant date fair value, beginning balance (in USD per share) $ 0    
Weighted average grant date fair value, granted (in USD per share) 50.00    
Weighted average grant date fair value, ending balance (in USD per share) 50.00 $ 0  
Weighted average grant date fair value, expected to vest (in USD per share) $ 50.00